Bacwkground. Several recent studies suggest that activation of ATP-dependent potassium (KATp) channels in the myocardium plays an important cardioprotective role during ischemia. The present study was undertaken to examine further the role of this ion channel in vivo in a model of "stunned" myocardium.
Bacwkground. Several recent studies suggest that activation of ATP-dependent potassium (KATp) channels in the myocardium plays an important cardioprotective role during ischemia. The present study was undertaken to examine further the role of this ion channel in vivo in a model of "stunned" myocardium. Methds and Resuls. Barbital-anesthetized dogs were subjected to 15 minutes of left anterior descending (IAD) coronary artery occlusion followed by 3 hours of reperfusion. Regional myocardial blood flow was measured by radioactive microspheres and segment function by sonomicrometry. Intravenous administration of the potassium channel opener aprikalim (RP 52891) at a dose that produced no significant systemic hemodynamic effects (10 sg/kg plus 0.1 pg/kg/min) resulted in a marked improvement in segment shortening in the ischemic/reperfused myocardium compared with control animals (p<O.05) when given before the ischemic insult. However, administration ofaprkalim immediately before reperfusion had no beneficial effect. Furthermore, pretreatment with the KATp channel antagonist glibenclamide antagonized the recovery of contractile function afforded by aprikalim when administered at a low dose (03 mg/kg) that alone had no effect on postischemic recovery. In contrast, pretreatment with either a higher dose of glibenclamide (1.0 mg/kg) or the related sulfonylurea KA channel antagonist tolbutamide (100 mg/lkg) resulted in a worsening of segment function after reperfusion. The ability of apikalim and the KATP channel antagonists to alter postischemic wail function occurred independently of differences in systemic hemodynamics, area at risk, and collateral blood flow during occlusion, the major determinants of the extent of myocardial stunning.
Conclons. These results suggest that opening myocardial KAT channels in the ischemic heart results in a marked cardioprotective effect in stunned myocardium and that these channels may serve an endogenous function, which is to provide protection from ischemic insults. (Cincuato 1992;86311-319) KEY WoRDs * myocardial ischemia * reperfusion * aprikalim * glibenclamide * tolbutamide A denosine triphosphate-dependent potassium (KATP) channels, a subtype of potassium channel modulated primarily by the intracellular concentration of ATP,' have been identified in several different tissue types, including pancreatic tissue,2 brain tissue,3 and cardiac,' vascular,4 and skeletal muscle. 5 Little is known of the function of KATP channels in these tissues with the exception of the pancreas, where they have been clearly demonstrated to be involved in the control of insulin secretion.6 However, several recent studies suggest that KATP channels in the myocardium may play an important cardioprotective role during ischemia. Cole et al7 showed in guinea pig ventricular walls that blocking KATP channels with glibenclamide worsened, and opening potassium channels with pinacidil enhanced, electrical and mechanical recovery after ischemia and reperfusion. In addition, Grover and coworkers8,9 showed that several potassium channel openers improved functional and metabolic recovery in globally ischemic rat hearts and that the beneficial effects of these agents could be blocked with glibenclamide. Thus, these studies suggest that activation of myocardial KATP channels during ischemia protects the myocardium.
The goal of the present study was to examine further the role of KATP channels during ischemia in vivo using a model of reversible ischemia/reperfusion injury ("stunned" myocardium) in barbital-anesthetized dogs. Aprikalim (RP 52891), a novel potassium channel opener previously reported to open KATP channels,10"11 was administered before occlusion or immediately before reperfusion, and glhbenclamide or tolbutamide, both sulfonylurea KATP channel antagonists, were administered before ischemia. To determine whether the cardioprotective effects of aprikalim were caused by KATP channel activation, we pretreated the animals with a low dose of glibenclamide. Methods
General Surgical Preparation
Mongrel dogs of either sex weighing between 20 and 30 kg were anesthetized with a combination of barbital (Tracer II) . Aortic blood pressure and left ventricular pressure were monitored by inserting a double pressure transducer-tipped catheter (PC 771, Millar Instruments, Houston, Tex.) into the aorta and left ventricle via the left carotid artery. Left ventricular dP/dt was recorded by electronic differentiation of the left ventricular pulse pressure and heart rate determined by a tachometer (Grass Instruments, Quincy, Mass.). The right femoral vein and artery were cannulated for drug administration and for the measurement of myocardial tissue blood flow, respectively.
A left thoracotomy was performed at the fifth intercostal space. The lung was carefully retracted and the heart suspended in a pericardial cradle. A 1.0-1.5-cm segment of the left anterior descending (LAD) coronary artery was dissected free from surrounding tissue distal to the first diagonal branch, and a calibrated electromagnetic flow probe (Statham SP 7515, Gould-Statham, Cleveland, Ohio) was placed around the vessel. A flowmeter (Statham 2202) was used to continuously measure LAD coronary blood flow. A micrometerdriven mechanical occluder was placed distal to the flow probe so that there were no branches between the flow probe and the occluder. The occluder was used to zero the flow probe and later to occlude the artery. A catheter was placed in the left atrium via the atrial appendage for the injection of radioactive microspheres. The hearts were paced at several beats (150-160 beats per minute) above the intrinsic rate with rectangular pulses of 4-msec duration and a voltage of approximately twice threshold through bipolar electrodes clipped to the left atrium. The ECG was monitored using limb lead II. All measurements were recorded at various times throughout the experiment on a Grass model 7 polygraph.
Myocardial Segment Shortening
Myocardial segment function was measured in the regions perfused by the LAD and left circumflex (LCx) coronary arteries by two sets of piezoelectric crystals inserted 7-9 mm into the subendocardium. The leads of the crystals were connected to an ultrasonic amplifier, which transforms the crystal-transmitted sound pulse into an electrical signal proportional to the distance between them. The tracings were monitored with an oscilloscope (Soltec Model 520). Diastolic segment length (DL) was determined at the beginning of the rise phase of positive dP/dt (onset of isovolumic contraction), and systolic segment length (SL) was determined at peak negative dP/dt. The percent segment shortening (%SS) was calculated with the equation %SS=(DL-SL)/ DLx 100. The segment length data were normalized by use of a value of 10.0 for the control DL. Area at Risk and Myocardial Blood Flow Area at risk was determined by injecting india ink into the LAD at the site of the occlusion at the end of the experiments, and regional myocardial blood flow in the subepicardium, midmyocardium, and subendocardium of the normal and ischemic regions was measured by the radioactive microsphere technique as previously described. 12 Transmural collateral blood flow within each region was calculated as the weighted average of the three layers.
Experimental Protocol
The experimental design (see Figure 1 ) included a control measurement of hemodynamics, segment shortening, regional blood flow, and blood glucose concentration after instrumentation and a sufficient recovery period from surgery. Subsequently, the LAD was occluded for 15 minutes and then reperfused for 3 hours. At the end of the ischemic period, LAD coronary blood flow was immediately returned to baseline levels by means of the mechanical occluder, where it was carefully maintained by slowly releasing the occlusion until no evidence of a hyperemic response was evident. The occluder was generally removed after 15-25 minutes of regulating the flow at preocclusion values. Hemodynamics and segment function were continuously recorded, and regional blood flow was measured at 12 minutes of occlusion. Blood glucose levels were also measured at 12 minutes of occlusion and at 3 hours of reperfusion.
Dogs were randomly assigned to one of seven treat- occlusion or immediately before reperfusion, glibenclamide (0.3 or 1.0 mg/kg) or tolbutamide (100 mg/kg) given as a bolus before occlusion, or aprikalim (10 pg/kg bolus plus 0.1 ,ug/kg/min infusion given before occlusion) after pretreatment with glibenclamide (0.3 mg/kg bolus).
Exclusion Criteria Animals were excluded from data analysis according to the following criteria: 1) ventricular fibrillation at any point throughout the experiment, 2) transmural blood flow in the central ischemic region >0.25 ml/min/g, and 3) presence of heartworms.
Statistics
All values in graphs, figures, and text are mean+SEM. Differences between groups in hemodynamics, segment shortening, regional myocardial blood flow, and blood glucose were compared by two-way ANOVA with repeated measures and Fisher's least significant difference. Differences within groups in hemodynamics, blood flow, and blood glucose were compared by one-way ANOVA and Dunnett's t test. Area-at-risk weights were compared by one-way ANOVA and Fisher's least significant difference. A value of p<0.05 was considered statistically significant.
Results

Mortality and Exclusions
Initially, 67 dogs were used in the study; however, 18 were excluded because of ventricular fibrillation (aprikalim pretreatment and glibenclamide 1.0 mg/kg groups, three dogs each; control and aprikalim posttreatment groups, two dogs each; and glibenclamide 0.3 mg/kg, aprikalim plus glibenclamide combination, and tolbutamide groups, one dog each) or high collateral blood flow during occlusion (control, aprikalim pretreatment, aprikalim posttreatment, aprikalim plus glibenclamide combination, and tolbutamide groups, one dog each). Thus, a total of 49 dogs were included in data analysis: seven in the control group, six in the group administered aprikalim throughout the entire experiment, seven in the group administered aprikalim only during reperfusion, eight in the low-dose glibenclamide group, seven in the higher-dose glibenclamide group, seven in the tolbutamide group, and seven in the group that received the combination of aprikalim and glibenclamide.
Hemodynamics
The hemodynamic data are summarized in Table 1 . There were no significant differences in heart rate, mean aortic blood pressure, left ventricular dP/dt, ratepressure product, or LCx coronary blood flow between groups throughout the experiments, with the exception of an increase in LCx coronary blood flow at 3 hours of reperfusion in the group given aprikalim only during reperfusion and an increase in LCx coronary blood flow, expressed as a percentage of the pretreatment value within individual groups, at 5 and 15 minutes of occlusion in the group of animals that were pretreated with aprikalim.
Area at Risk
The anatomic area at risk expressed as a percentage of the left ventricle was not significantly different between groups: control, 26 Regional Myocardial Blood Flow
Regional myocardial blood flow in the nonischemic (LCx) and ischemic/reperfused (LAD) regions is summarized in Table 2 and Figure 2 . In the nonischemic region, there were no differences in regional blood flow before or during the occlusion period. Similarly, in the ischemic/reperfused region, there were no significant differences in control blood flow or collateral flow during occlusion ( Figure 2 ). This suggests that all groups were subjected to equivalent degrees of ischemia.
Myocardial Segment Shortening
There were no significant differences in segment function between the groups in the nonischemic LCx region at any time throughout the experiment (data not shown). Segment function in the ischemic LAD region expressed as %SS in dogs given aprikalim before occlusion and when given immediately before reperfusion is shown in Figure 3 . There was marked improvement in %SS during reperfusion when aprikalim was administered before the occlusion period compared with salinetreated animals. When aprikalim was given immediately before reperfusion, %SS was equivalent to the control group. Figure 4 shows %SS in the ischemic region in dogs pretreated with 0.3 mg/kg of glibenclamide alone and those given the combination of glibenclamide plus aprikalim given before occlusion and throughout the remainder of the experiment. Glibenclamide had no effect on %SS itself; however, it completely blocked the beneficial effects of aprikalim on reperfusion contractile function. As this dose of glibenclamide had no effect on functional recovery by itself, these data suggest that aprikalim is mediating its beneficial effects by opening KATP channels. Finally, Figure 5 shows the effects of the higher dose of glibenclamide and tolbutamide on %SS in the ischemic/reperfused region. Glibenclamide significantly exacerbated the reduction in %SS that occurred during the occlusion period and also worsened reperfusion function at 5, 15, 60, and 180 minutes of reperfusion compared with control animals. Similarly, tolbutamide worsened the recovery of %SS at 5, 15, 30, 60, and 120 minutes of reperfusion. Blood Glucose Levels Blood glucose levels in the saline-, aprikalim-, and glibenclamide-treated groups are shown in Table 3 . Blood glucose levels were significantly depressed at 3 hours of reperfusion in all animals given glibenclamide compared with their pretreatment control values; however, glucose was significantly reduced in dogs given the combination of aprikalim and glibenclamide only when compared with the corresponding time point in control animals. 
bpm, Beats per minute; MBP, mean arterial blood pressure; LV dP/dt, left ventricular dP/dt; RPP, rate-pressure product; CBF, left circumflex coronary artery blood flow; AP, aprikalim; occ, occlusion; rep, reperfusion; glib, glibenclamide; tolb, tolbutamide. Values are mean+SEM. *p<0.05 vs. pretreatment values within individual groups. tp<0.05 vs. corresponding time value in the control group.
Discussion
The goal of the present study was to examine the possible cardioprotective role of myocardial KATP channels in a model of stunned myocardium in dogs. Initially, we observed that systemic administration of a nonhypotensive dose of the potassium channel opener aprikalim markedly improved postischemic wall function after a 15-minute LAD occlusion compared with saline-treated dogs. The improvement in function produced by aprikalim was probably a result of KATP channel activation during ischemia, because it was effective only when administered before the occlusion period and not effective when given immediately before reperfusion, and because a low dose of glibenclamide completely blocked the protective effects of aprikalim. Importantly, this dose of glibenclamide (0.3 mg/kg) had no effect on the degree of stunning when administered alone. Subsequently, we found that pretreatment with a higher dose of glibenclamide or the chemically related KATP channel antagonist tolbutamide resulted in significant worsening of segment shortening during reperfusion. The beneficial effects of aprikalim and the deleterious effects of the KATP channel antagonists occurred independently of differences in systemic hemodynamics, collateral blood flow, and ischemic bed size. Taken together, these results suggest that activation of myocardial KATP channels during ischemia protects the myocardium from reversible ischemia/reperfusion injury in barbital-anesthetized dogs and that these channels may serve an essential physiological function of affording cardioprotection during ischemia.
Several studies support this hypothesis. Recently, it has been shown that the increase in potassium conductance and shortening of action potential duration that reported that antagonizing KATP channel opening during ischemia with glibenclamide worsened electrical and mechanical function during reperfusion after no-flow ischemia in isolated guinea pig ventricular walls. The effect of glibenclamide was concentration dependent and correlated directly with the rate of inhibition of action potential shortening. Thus, these studies alluded to the possibility that KATP channel opening that occurs during ischemia as intracellular ATP levels decline serves an endogenous protective role. In support of this hypothesis, we have shown that blocking KATP channels increases infarct size18 and antagonizes the protective effects of ischemic preconditioning on infarct size in dogs. 19 The present studies further show that activation of KATP channels plays a modulatory role in the pathogenesis of myocardial stunning.
There is also substantial evidence that activation of myocardial KATP channels with potassium channel openers provides protection to the ischemic myocardium. Compounds with this mechanism of action have been shown to improve functional recovery and reduce lactate dehydrogenase release from isolated rat hearts8'9 and to prevent electrical and mechanical dysfunction in guinea pig ventricular walls7 after global ischemia and reperfusion. In the rat heart studies, the beneficial effects of the potassium channel openers were attributed to KATP channel activation because glibenclamide or sodium 5-hydroxydecanoate, both blockers of the KATP channel, antagonized these favorable effects.8'9
Furthermore, Grover and coworkers9 '20 demonstrated in anesthetized dogs that intracoronary administration of cromakalim attenuated stunning and intracoronary administration of both cromakalim and pinacidil reduced infarct size. 9 Conversely, it has been reported that systemic administration of pinacidil had no effect21 or increased infarct size22 in conscious dogs. However, in these studies, pinacidil was administered at a dose that produced a reflex-induced increase in oxygen consumption and a decrease in collateral blood flow secondary to hypotension; therefore, it is not surprising that infarct size was not changed or even increased. Subsequently, our laboratory demonstrated that systemic administration of aprikalim18 or EMD 5643123 at nonhypotensive doses resulted in a reduction in infarct size or attenuated stunning in anesthetized dogs, respectively. Furthermore, the beneficial effects of these agents were antagonized by glibenclamide. Thus, taken together, the results of previous in vitro and in vivo studies and those of the present study with aprikalim suggest that potassium channel openers exert direct cardioprotective effects during ischemia by opening myocardial KATP channels. The finding that potassium channel openers are cardioprotective at doses that are nonhypotensive is surprising, because these drugs are more potent at opening potassium channels in vascular smooth muscle than in the myocardium in vitro. [24] [25] [26] In general, potassium channel openers produce vascular relaxation in the 1 ,uM range, whereas they shorten action potential duration and decrease contractility in the 10-300 uM range. However, recent studies in cardiac myocytes27 showed that RP 49356, a racemic mixture of which aprikalim is the active enantiomere, and cromakalim opened KATP channels and reduced contractile activity more effectively when the intracellular concentration of ATP declined. These findings suggest that potassium channel openers may selectively activate KATP channels in ATPdepleted tissues, such as the ischemic myocardium, at low doses that are without effect in normal tissues.
The mechanism by which myocardial KATP channel opening attenuated postischemic contractile dysfunction is not readily apparent in the present study; the most likely explanation, however, is that KATP channel activation results in a reduction in calcium overload during ischemia secondary to action potential shortening and prevention or attenuation of membrane depolarization. It is well established that the free cytosolic calcium concentration rises to abnormal levels during ischemia."'-30 This increase in calcium is thought to activate various calcium-dependent enzymes that are detrimental for cell function as well as to squander valuable ATP in an attempt to normalize intracellular calcium gradients.31,32 That increased intracellular cal-cium is important in the pathogenesis of stunning has been demonstrated in studies in which inhibitors of calcium overload during ischemia, such as calcium channel blockers33,34 and ryanodine,35 improve functional recovery after short periods of occlusion and reperfusion. Theoretically, KATP channel opening, either in response to ischemia or by potassium channel openers, would reduce calcium influx during ischemia by shortening action potential duration and thus attenuate membrane depolarization. These events would be expected to rapidly reduce contractile activity, reduce the open time of voltage-regulated calcium channels, and maintain the Na+/Ca2`exchanger in a productive calcium extrusion mode and delay or prevent its reversal to calcium intrusion, an event that may contribute significantly to calcium accumulation during ischemia. 32 The present study suggests that modulation of myocardial KATP channels was responsible for the effects of aprikalim and the KATP channel antagonists; it is possible, however, that the drugs were acting at potassium channels other than those in cardiac muscle. Potassium channel openers have been demonstrated to increase coronary blood flow" and collateral blood flow, 36 and glibenclamide has been shown to decrease coronary blood flow and to interfere with hypoxic vasodilation37 by interacting with potassium channels in vascular smooth muscle. Because previous studies demonstrate that collateral blood flow38 and blood flow immediately after release of the occlusion'2 and throughout reperfu-sion39 play an important role in determining the extent of stunning, in the present study aprikalim may have improved contractile function by increasing, and glibenclamide or tolbutamide may have worsened function by decreasing, blood flow to the LAD region. However, there were no differences in collateral flow between groups during the occlusion period as measured by radioactive microspheres ( Table 2 and Figure 2) , and there were no differences in LAD coronary blood flow during reperfusion except for a slight increase at 5 and 15 minutes of reperfusion in the group of animals given aprikalim before occlusion and an increase after 3 hours of reperfusion in the group of animals given aprikalim immediately before reperfusion (Table 1) . Although it is possible that the increased reperfusion blood flow in the aprikalim pretreatment group may explain the improved segment function observed, it seems unlikely, because segment function was markedly improved, whereas blood flow was only slightly increased. Thus, changes in blood flow during the occlusion or reperfusion periods do not appear to be responsible for the effects of aprikalim and the KATP channel antagonists in the present experiments.
Another possibility by which aprikalim and the KATP channel antagonists may have affected stunning is via alterations in blood glucose and/or insulin levels. Glibenclamide and tolbutamide have been shown to increase insulin secretion from the pancreas by blocking KATP channels in 13-cells.6 In contrast, most potassium channel openers, including aprikalim, do not stimulate insulin secretion.40 In the present experiments, glibenclamide reduced blood glucose levels at 3 hours of reperfusion; at the critical time during the occlusion period, however, there were no differences in blood glucose levels between groups. Furthermore, as blood glucose tended to be depressed in all groups that received glibenclamide yet %SS during reperfusion was different from control animals only in the high-dose glibenclamide group, it seems unlikely that a metabolic effect secondary to changes in blood glucose and/or insulin levels is responsible for the differences in segment function observed. The observations of others as well as those of the present study, which demonstrate a protective role of KATP channel opening during myocardial ischemia, may have several important clinical implications. First, interventions that prevent myocardial KATP channels from opening in patients undergoing an ischemic episode may be expected to worsen ischemic damage. This is especially important because sulfonylurea KATP channel antagonists are currently being investigated as potential antiarrhythmic agents because of their ability to prevent ischemia-induced action potential shortening. Furthermore, enhancing or accelerating myocardial KATP channel opening during ischemia with potassium channel openers may prove to be an effective treatment for myocardial ischemia/reperfusion injury. That aprikalim had a beneficial effect that was selective for the ischemic area in the absence of changes in systemic hemodynamics further suggests that these drugs may be valuable as more appropriate and specific treatment of ischemic heart disease and that they may have advantages over other drugs with related mechanisms of action, such as the calcium channel blockers. Since KATP channel acti- vation has been shown to be proarrhythmic41,42 as well as antiarrhythmic,4344 additional future studies are necessary to more clearly define the role of these channels in cardiac arrhythmia formation or suppression during ischemia and reperfusion. 
